stoxline Quote Chart Rank Option Currency Glossary
  
Adial Pharmaceuticals, Inc. (ADIL)
1.12  0.02 (1.82%)    06-21 16:00
Open: 1.13
High: 1.17
Volume: 272,328
  
Pre. Close: 1.1
Low: 1.06
Market Cap: 5(M)
Technical analysis
2024-06-21 4:50:24 PM
Short term     
Mid term     
Targets 6-month :  1.6 1-year :  1.83
Resists First :  1.37 Second :  1.57
Pivot price 1.28
Supports First :  1.05 Second :  0.88
MAs MA(5) :  1.21 MA(20) :  1.28
MA(100) :  1.52 MA(250) :  2.57
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  15.6 D(3) :  23.2
RSI RSI(14): 36.8
52-week High :  14 Low :  0.76
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADIL ] has closed above bottom band by 1.4%. Bollinger Bands are 70.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.17 - 1.18 1.18 - 1.18
Low: 1.04 - 1.05 1.05 - 1.06
Close: 1.11 - 1.12 1.12 - 1.13
Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Headline News

Thu, 20 Jun 2024
Adial Pharmaceuticals Announces Publication in Leading - GlobeNewswire

Thu, 20 Jun 2024
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For ... - Benzinga

Wed, 10 Apr 2024
EXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient ... - Benzinga

Wed, 10 Apr 2024
Adial stock rallies 81% on data for alcohol abuse drug (NASDAQ:ADIL) - Seeking Alpha

Wed, 10 Apr 2024
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today? - InvestorPlace

Tue, 02 Apr 2024
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 4 (M)
Held by Insiders 4 (%)
Held by Institutions 7.7 (%)
Shares Short 167 (K)
Shares Short P.Month 9 (K)
Stock Financials
EPS -4.99
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.45
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -82.3 %
Return on Equity (ttm) -190.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.63
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.23
PEG Ratio 0
Price to Book value 0.45
Price to Sales 0
Price to Cash Flow -0.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android